CEO Today Business Women of the Year Awards

49 www.ceotodaymagazine.com CEO Today Business Women of the Year Awards 2018 USA KELLY LONDY CEO of Lumicell FIRM PROFILE Since its inception, Lumicell has relentlessly pursued the development of new technologies and processes that allow surgeons to remove all cancer in the first surgery. In breast cancer alone, up to 30 percent of lumpectomy patients require a second surgery — adding close to $1 billion per year in healthcare costs. Secondary surgeries also result in 30 to 50 percent more tissue removal than necessary, as well as a prolonged surgery time. Second surgeries can often increase discomfort, amplify the emotional toll and create cosmetic expenses for patients. Lumicell, an innovator in image-guided cancer surgery technology, develops a comprehensive solution to overcome limitations in detecting all cancer cells that are notoriously evasive. The company’s technology enables surgeons to visualize and distinguish cancerous cells from healthy cells to ensure tumor cells aren’t left behind during surgery. Lumicell’s digital biology platform — the LUM System — was designed by leading engineers and scientists through partnerships with the Massachusetts Institute of Technology (MIT) and Harvard Medical School and collaborations with surgeons from leading academic centers. These experts continue to advance the LUM System as a new standard for real-time technology that completely removes cancer cells while sparing healthy tissue. The LUM System is comprised of three unified components: drug, device and decision software. The system guides surgeons to real-time detection and removal of cancer cells remaining in the invasive front in the cavity — beyond the margin. The LUM System includes a preoperative fluorescent agent that finds cancer cells in the tumor micro environment. It selectively targets the physiology of the tumor’s invasive front within the tumor micro environment where cancer cells interact with cancer-associated immune cells. When cancer cells are detected, the agent produces a fluorescent signal. The LUM device is a hand-held imaging tool used after removal of the tumor specimen to instantly scan cavity walls and view activated fluorescent cells. LUM software instantly displays the image from the cavity on a monitor and guides the surgeon to remove cancerous tissue. Lumicell technology is currently being clinically evaluated in five cancer indications—breast, prostate, colorectal, esophageal and pancreatic — in more than 15 medical centers across the U.S. Additional solid tumor clinical protocols, including ovarian and brain cancer, have been submitted for FDA approval. Lumicell’s comprehensive strategy has the potential to improve patient outcomes and experience while driving down costs for the providers. ABOUT KELLY LONDY Kelly Londy, chief executive officer and member of the board of directors at Lumicell, Wellesley, Mass., has been on a path to leadership since her early days working at the University of Michigan Medical Centers. Throughout her 25-year tenure in the medical device field, Londy has applied her practical and clinical experience gained in roles of increasing responsibility and business stewardship. Londy, a Six Sigma Blackbelt, combined her expertise in imaging and related technologies with a passion for analytics, innovation and patient-focused solutions. Formerly chief operating officer at Accuray, Londy provided leadership across all customer-facing activities — from product development through customer adoption, education and service. Prior to serving as COO at Accuray, she led the company’s customer-centric initiatives as chief commercial officer. In that role, she served a complex ecosystem of constituents, including radiation oncologists, surgeons, neurosurgeons, dosimetrists, hospital executives, insurance companies and patients. She was one of the early voices in the market calling for patients to have more information, insight and greater control over their healthcare decisions. Prior to joining Accuray, Londy served as vice president and general manager of Molecular Imaging at GE Healthcare North America, where she led a multi-business strategy to improve cost, quality and access to new technologies. At GE, she progressed through women’s health, MRI and corporate accounts as a path to better understand how leading technology can improve patient outcomes and customers’ return on investment. She has also held leadership roles at Philips Healthcare North America. Londy joined Lumicell in July of 2017 to guide the company toward its ongoing mission to change the landscape of cancer surgery. In addition to leading innovation and operational aspects, she’s focused on making Lumicell technology available to all patients, not just the economically advantaged. Londy is passionate about the battle against cancer and improving the lives of patients and families — a perfect alignment with the origins of Lumicell. www.lumicell.com